ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis

The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, November 10, 2022
Information
Tags: 
Health, Medical Devices, Neurology, Health Technology, Research, Science, Biotechnology, Quality of life, ARC, Forward-looking statement, Health, Partnership, Research, CHUV, Technology, Swiss Federal Institute of Technology, Spinal cord, Neuron, Science, Leg, Spinal cord injury, Lausanne University Hospital, Muscle, SCI, Movement, Company, Program, Walking, Materials Research Science and Engineering Centers, Euronext, Hyperreflexia, EPFL, CEO, U.S. FDA, Swiss Federal Institute of Aquatic Science and Technology, Paralysis, Medical device, Trapping, Nature
Geotags: 
NETHERLANDS, NORTH AMERICA, UNITED STATES, SWITZERLAND, EUROPE, MASSACHUSETTS, BOSTON
⚠ partially generated by AI ↴
Organisation: 
ONWARD MEDICAL, ONWARD MEDICAL N.V.
Stock Symbol: 
AEX:ONWD
BSE:ONWD
Summary
Key Points: 
  • The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • ONWARDs work builds on more than a decade of basic science and preclinical research conducted at the worlds leading neuroscience laboratories.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.


ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported that a new study by scientists at .NeuroRestore, ONWARD’s research partner, has identified the specific neurons that are activated and remodeled by spinal cord stimulation, enabling individuals with spinal cord injury to stand, walk and rebuild their muscles. This discovery marks a fundamental, scientific breakthrough. The study was published yesterday in Nature.

In the multi-year STIMO study, coordinated by .NeuroRestore’s co-directors – Grégoire Courtine, a neuroscience professor at EPFL and Chief Scientific Officer of ONWARD, and Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital (CHUV) – participants with paralysis due to spinal cord injury underwent targeted epidural electrical stimulation of the area of the spinal cord that controls leg movement. Remarkably, all participants regained motor function and the ability to walk. Three participants in the study pioneered use of an innovative lead developed by ONWARD to specifically target the areas of the spinal cord involved in leg and lower trunk movement with the intent to facilitate faster and more effective recovery of motor function.

The scientists believe it is crucial to understand exactly how neuronal reorganization occurs to develop more effective treatments and improve the lives of as many people as possible. The press release by EPFL can be found here.

“The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis. As a result of this study and its accompanying scientific breakthrough, ONWARD and its research partners have learned precisely where to place the epidural lead and how to program stimulation to facilitate walking,” said Dave Marver, CEO of ONWARD. “This important work is enabling us to develop a therapy for people with spinal cord injury that aims to be precise, repeatable, and scalable.”

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.

ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

Disclaimer

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Copyright: 
Copyright Business Wire 2022